Raymond James Lowers Johnson & Johnson (NYSE:JNJ) Price Target to $162.00

Johnson & Johnson (NYSE:JNJ) had its price objective reduced by Raymond James from $165.00 to $162.00 in a research report released on Monday,Benzinga reports. Raymond James currently has an outperform rating on the stock.

Several other brokerages also recently issued reports on JNJ. Stifel Nicolaus lowered their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Leerink Partners dropped their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Finally, Barclays upped their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Eight investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $171.50.

Johnson & Johnson Trading Up 1.5 %

Shares of NYSE JNJ opened at $154.08 on Monday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock has a market cap of $371.31 billion, a price-to-earnings ratio of 23.17, a P/E/G ratio of 2.56 and a beta of 0.49. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company’s fifty day moving average is $159.38 and its 200-day moving average is $155.11.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same period in the prior year, the company earned $2.29 earnings per share. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. Equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

Several hedge funds have recently added to or reduced their stakes in the company. Yousif Capital Management LLC increased its position in Johnson & Johnson by 0.9% during the 1st quarter. Yousif Capital Management LLC now owns 337,020 shares of the company’s stock worth $55,891,000 after buying an additional 2,937 shares during the period. Regatta Capital Group LLC increased its position in Johnson & Johnson by 3.1% during the first quarter. Regatta Capital Group LLC now owns 5,106 shares of the company’s stock worth $847,000 after acquiring an additional 155 shares during the period. Octavia Wealth Advisors LLC raised its stake in Johnson & Johnson by 2.8% in the 1st quarter. Octavia Wealth Advisors LLC now owns 14,270 shares of the company’s stock worth $2,367,000 after purchasing an additional 385 shares in the last quarter. Investment Advisory Group LLC boosted its holdings in Johnson & Johnson by 1.6% in the 1st quarter. Investment Advisory Group LLC now owns 4,777 shares of the company’s stock valued at $792,000 after purchasing an additional 77 shares during the period. Finally, Henrickson Nauta Wealth Advisors Inc. increased its holdings in shares of Johnson & Johnson by 9.8% during the first quarter. Henrickson Nauta Wealth Advisors Inc. now owns 1,604 shares of the company’s stock worth $266,000 after purchasing an additional 143 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.